RNS Announcements

Director/PDMR Shareholding

05 November 2024

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce that Mark Collingbourne, PBX’s Company Secretary, has acquired 80,000 ordinary shares in the Company. Following this acquisition, Mr. Collingbourne is interested in 91,093 ordinary shares in the Company.

Further information about this acquisition is set out in the table below.

 

For further information, please contact:

 

ProBiotix Health plc https://probiotixhealth-ir.com
Steen Andersen, Chief Executive Officer Contact via Walbrook below
  
Peterhouse Capital Limited
(Aquis Corporate Adviser and Broker) 		 
 
Mark Anwyl
  		Tel: 020 7220 9793
 
Walbrook PR Ltd [email protected]
Anna Dunphy Mob: 07876 741 001

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Mark Collingbourne
2 Reason for the notification
a) Position/status Company Secretary
b) Initial notification /Amendment  
Initial
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor
a) Name ProBiotix Health plc
b) LEI 98450048683CF0388C30
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument
Identification code 		 
ordinary shares of 0.05p each
 
 
 
 
ISIN: GB00BLNBFR86
b) Nature of the transaction Acquisition of ordinary shares
c) Price(s) and volume(s) 80,000 ordinary shares @ 5.5p per share
d) Aggregated information
- Aggregated volume
- Price 		 
 
n/a
e) Date of the transaction 1 November 2024
f) Place of the transaction Aquis Growth Market

 

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

If you would like to keep up to date with commercial news, please follow ProBiotix Health on LinkedIn